Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation ...

In Evaluate’s recently released annual World Preview Report, including updated global pharmaceutical market projections ...

The Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Angelini has fallen short of its standards by ...

Novo Nordisk has just released the topline findings from two eagerly anticipated phase 3 trials of its oral formulation of ...

Whilst the NHS indubitably runs on international talent, however, this does not stop our system from pushing overseas nurses ...

The positive result in OCEANIC-STROKE means that asundexian can potentially now sit alongside prostate cancer therapy Nubeqa ...

J&J is also running mid-stage trials of a tau active immunotherapy codenamed JNJ-2056 for Alzheimer's, while other active tau ...

Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group of companies ...

Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide, cutting the monthly price to $349, earlier than expected, for people willing to ...

Now in its 7th year, our free-to-attend careers event will be held at the Royal Society of Medicine on the 18th February 2026 ...

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix, an emerging, clinical-stage biotech company ...

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...